# Selumetinib (AZD6244, ARRY-142886) J-BTC Phase 1 Study

> **NCT01949870** · PHASE1 · TERMINATED · sponsor: **AstraZeneca** · enrollment: 6 (actual)

## Conditions studied

- Inoperable Locally Advanced or Metastatic Biliary Tract Cancer

## Interventions

- **DRUG:** Cisplatin
- **DRUG:** Gemcitabine
- **DRUG:** Selumetinib

## Key facts

- **NCT ID:** NCT01949870
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2013-10
- **Primary completion:** 2014-08
- **Final completion:** 2014-08
- **Target enrollment:** 6 (ACTUAL)
- **Why stopped:** change in the development strategy
- **Last updated:** 2016-05-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01949870

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01949870, "Selumetinib (AZD6244, ARRY-142886) J-BTC Phase 1 Study". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01949870. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*